SCIENTECH (02291), also known as LEPU ScienTech Medical Technology (Shanghai), saw its stock price surge by 5.06% in intraday trading on Monday. The significant uptick comes as the company released its impressive first-half 2025 financial results, showcasing robust growth and improved profitability.

According to the report, SCIENTECH's revenue for the first half of 2025 reached CN¥329.7 million, marking a substantial 32% increase compared to the same period in 2024. The company's net income also saw a notable rise of 30%, reaching CN¥182.0 million. Earnings per share (EPS) improved from CN¥0.40 in the first half of 2024 to CN¥0.53 in the current reporting period, representing a 32.5% increase.

While the company's profit margin slightly decreased from 56% to 55% due to higher expenses, SCIENTECH's overall performance remains strong. Looking ahead, analysts forecast the company's revenue to grow at an average rate of 38% per annum over the next two years, outpacing the 18% growth projected for the Hong Kong Medical Equipment industry. This positive outlook, combined with the impressive first-half results, appears to have fueled investor confidence, driving the stock's significant price increase.